【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Cancer Treatments
2.1 The Physiology of Cancer – Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer – Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival – Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World – More Must Be Done
2.3 Treating Tumours – How Can We Fight Back?
2.3.1 Chemotherapy – The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy – A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents
3. The World Anti-Cancer Drugs Market, 2015-2025
3.1 Global Anti-Cancer Drugs Market Forecast, 2015-2025
3.2 The Domination of Immunotherapies in 2014
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2015-2025 – The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2015-2025
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2015-2025 – A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2015-2025
4. Leading National Markets, 2015-2025
4.1 Anti-Cancer Drugs – Leading Markets, 2014
4.2 The US Anti-Cancer Drugs Market, 2015-2025 – Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2014
4.2.2 The US Anti-Cancer Drugs Market Forecast – A Matured Approach
4.2.3 The Effect of Regulations on the US Market
4.3 The Japanese Anti-Cancer Drugs Market, 2015-2025 – Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2015-2025 – Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2015-2025 – Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2015-2025 – Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2015-2025 – Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2015-2025 – Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2015-2025 – Can it Reach its Potential?
5. The Top 25 Anti-Cancer Drugs: Revenue Forecasts, 2015-2025
5.1 Avastin (Roche) – The World Market Leader
5.1.1 Avastin Revenue, 2011-2014 – Mixed Growth
5.1.2 Avastin Revenue Forecast – Still No.1?
5.2 Herceptin (Roche) – The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2011-2014 – Still Rising
5.2.2 Herceptin Revenue Forecast – Generic Erosion
5.3 Rituxan/MabThera (Roche) – Slowing Growth
5.3.1 Rituxan Revenue, 2011-2014 – Still Strong
5.3.2 Rituxan Revenue Forecast – Heading for a Decline
5.4 Gleevec/Glivec (Novartis) – The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2011-2014
5.4.2 Glivec Revenue Forecast – What Does the Future Hold?
5.5 Revlimid (Celgene) – Celgene’s Top Revenue Generator
5.5.1 Revlimid Revenue, 2011-2014 – Still on the Rise
5.5.2 Revlimid Revenue Forecast – A Long Term Leader?
5.6 Alimta (Eli Lilly) – A Slow Decline?
5.6.1 Alimta Revenue, 2011-2014
5.6.2 Alimta Revenue Forecast – Revenue Erosion Looming
5.7 Velcade (J&J/Takeda) – Rising Steadily
5.7.1 Velcade Revenue, 2011-2014
5.7.2 Velcade Revenue Forecast – A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/Merck KGaA) – Facing Tough Competition
5.8.1 Erbitux Revenue, 2011-2014
5.8.2 Erbitux Revenue Forecast – No More Growth?
5.9 Gardasil (Merck & Co.) – The Rise of Prevention
5.9.1 Gardasil Revenue, 2011-2014
5.9.2 Gardasil Revenue Forecast – Still Growing Strong
5.10 Zytiga (Johnson & Johnson)
5.10.1 Zytiga Revenue, 2011-2014 – The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) – Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2011-2014 – The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast – A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2011-2014 – No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) – A Targeted Approach
5.13.1 Afinitor Revenue, 2011-2014 – Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2011-2014
5.14.2 Sprycel Revenue Forecast – How Long Will the Growth Last?
5.15 Tasigna (Novartis) – Moving Up
5.15.1 Tasigna Revenue, 2011-2014
5.15.2 Tasigna Revenue Forecast – A Multi-Billion Dollar Product?
5.16. Sutent (Pfizer)
5.16.1 Sutent Revenue, 2011-2014
5.16.2 Sutent Revenue Forecast – No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2011-2014 – The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast – A Promising Start
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2011-2014 – The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2011-2014
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) – Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2014
5.20.2 Yervoy Revenue Forecast – Will Sales Keep Growing?
5.21 Vidaza (Celgene) – What Growth Potential?
5.21.1 Vidaza Revenue, 2011-2014
5.21.2 Vidaza Revenue Forecast – Generic Impact?
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2011-2014
5.22.2 Treanda Revenue Forecast – Stalled Growth?
5.23 Temodar/Temodal (Merck & Co.) – Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2011-2014
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) – The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2011-2014
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) – Beginning the Climb
5.25.1 Abraxane Revenue, 2011-2014
5.25.2 Abraxane Revenue Forecast
6. Drugs Approved in 2014-2015: Potential Future Blockbusters
6.1 Approved Treatments in 2015
6.1.1 Farydak (panobinostat/Novartis)
6.1.2 Ibrance (palbociclib/Pfizer)
6.1.3 Lenvima (lenvatinib mesylate/Eisai)
6.1.4 Opdivo (nivolumab/Bristol-Myers Squibb)
6.1.5 Unituxin (dinutuximab/United Therapeutics)
6.2 Approved Treatments in 2014
6.2.1 Beleodaq (belinostat/Spectrum Pharmaceuticals)
6.2.2 Blincyto (blinatumomab/Amgen)
6.2.3 Cyramza (ramucirumab/Eli Lilly): A Breakthrough for Gastric Cancer?
6.2.4 Imbruvica (ibrutinib/Pharmacyclics)
6.2.5 Keytruda (pembrolizumab/Merck)
6.2.6 Lynparza (olaparib/AstraZeneca)
6.2.7 Zydelig (idelalisib/Gilead)
6.2.8 Zykadia (ceritinib/Novartis) – The Rise of Kinase Inhibitors
6.2.9 Tafinlar (Novartis) – A Partner for Mekinist
6.2.10 Kadycla (Roche) – A Future Star
7. Leading Companies for Cancer Treatments, 2014
7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche – Leader of the Pack
7.2.1 Oncology Pipeline – Investment in the Future
7.2.2 Roche’s Future Direction in Cancer Treatment
7.3 Novartis – Closing the Gap on Roche
7.3.1 Oncology R&D Pipeline – What’s the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene – A Pressing Need to Diversify?
7.4.1 Celgene’s Oncology R&D Pipeline – Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly – Reliant on Alimta
7.5.1 Oncology R&D Pipeline – What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca – Climbing Up the Ladder
7.6.1 Oncology R&D Pipeline – Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology R&D Pipeline – What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck &Co. – Prominent in Vaccines
7.8.1 Oncology R&D Pipeline – Greater Focus on Cancer
7.8.2 The Future Direction of Merck
7.9 Johnson & Johnson
7.9.1 Oncology J&J Pipeline – A Focus on Prostate Cancer Drugs
8. R&D Pipelines for Cancer Treatment
8.1 Breast Cancer Drugs under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Veliparib (Abbvie)
8.1.3 NeuVax (Galena Biopharma)
8.1.4 Entinostat (Syndax)
8.2 Prostate Cancer Drugs under Development
8.2.1 ODM-201 (Orion) – Jointly Developed with Bayer
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs under Development
8.3.1 RG7446 (Roche)
8.3.2 Nivolumab (Bristol-Myers Squibb)
8.3.3 MEDI4736 (AstraZeneca)
8.3.4 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 HA-Irinotecan (Alchemia)
8.5 Cervical Cancer Drugs under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck & Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.9 Bladder Cancer Drugs under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin’s Lymphoma Drugs under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs under Development
8.12.1 IMA901 (Immatics)
8.12.2 AGS-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck & Co.)
9. Qualitative Analysis of the Anti-Cancer Drug Market 2015-2025
9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment’s Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment
10. Research Interviews from Our Survey
10.1 Dr Cesar M. Castro, Massachusetts General Hospital Cancer Center and Center for Systems Biology, Boston
10.1.1 D3 Enables Point-of-care and Real Time Testing of Tumours
10.1.2 The Use of D3 to Detect Cancer
10.1.3 D3 – Speed, Ease of Use, Low Cost and Accurate
10.1.4 D3 – Possibility of Detecting Various Types of Cancer
10.1.5 Further Development and Refinement
10.2 Dr Silvia Paddock, Senior Associate, Rose Li and Associates, Inc.
10.2.1 PACE CII – Meeting the Needs of a Diverse Range of Stakeholders
10.2.2 PACE CII – Main Components
10.2.3 PACE CII – a Flexible Framework for Objective Assessments of Progress
10.2.4 Value of Cancer Treatments – Dynamic and Complex
10.2.5 Multiple Stakeholders – Shared Perspectives on Treatment Goals?
10.2.6 Free Access to Database and Tool
11. Conclusions of the Study
11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies – The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US – Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment – It’s Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks
【レポート販売概要】
■ タイトル：がん治療薬の世界市場：企業動向、治療、研究開発、市場予測■ 英文：World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5081912
■ 調査対象地域：グローバル
- プロセス液体分析器の世界市場：PH/ORP計、導電率計、近赤外分析計、濁度計、溶存酸素計、塩素計、液体密度計、MLSS計、TOC計、アルミニウム計、アンモニア計、フッ素計The global process liquid analyzers market is expected to grow from USD 1.61 Billion in 2015 to USD 2.39 Billion by 2022, at a CAGR of 5.67% between 2016 and 2022. The market is majorly driven by the increase in the shale gas production in the U.S. and growing demand for water & wastewater treatment. In addition, factors such as increasing usage of process liquid analyzers in the emerging markets, …
- コネクテッド自動販売機の世界市場2016-2020About the Connected Vending Machine Market The vending machine industry has started to evolve from traditional machines to intelligent, or connected, machines. The industry has gone beyond just delivering snacks and is developing new and sophisticated retail solutions. Connected vending machines, unlike traditional machines, are engaging shoppers like never before with touchscreen controls, audio, …
- ヘキサメチレンジアミンの世界市場The report covers the important hexamethylenediamine global markets. It further divides the market on the basis of applications, and geography. The market data for these types is given with respect to volume (kilo tons) and value (USD Million). The market value of hexamethylenediamine was estimated at $2,904.2 million in 2014 and is projected to reach a CAGR of about 3.4% from 2014 to 2019. The da …
- 民間航空の飛行シミュレーション及びシミュレーション訓練の世界市場Flight simulation is an important factor in professional flight training for commercial pilots and can be used in initial and recurrent training as well as proficiency / annual checks of flight crew personnel that are mandated by international regulators and standard operational procedures of aircraft operators. Flight simulation is vital for enhancing flight skill competency and situational aware …
- バイオセンサーの世界市場分析：、用途別（医療用、食品毒性検出、工程制御、農業、環境）、技術別（熱バイオセンサー、電気化学バイオセンサー、圧電バイオセンサー、光学バイオセンサー）、エンドユーザー別（家庭用ヘルスケア診断、ポイントオブケア検査、食品産業、研究所）、セグメント予測、-2020Global biosensors market is expected to reach USD 21.17 billion by 2020. Biosensors, owing to their capability to resolve various analytical issues in diverse areas such as medicine, pharmacology, food & agriculture safety and defense, are expected to witness a rapid growth in demand over the next six years. Increasing demand for specific detection techniques for early diagnosis in the healthcare …
- 高速攻撃艇（FAC）の世界市場2017-202：ミサイル搭載FAC、ミサイル非搭載FACAbout Fast Attack Craft FAC are small, fast, agile, and attack-capable warships, which are armed with anti-ship missiles, guns, or torpedoes. FAC are generally operated in the coastal regions as they lack the defensive capabilities to survive in the blue waters. The major benefit of such ships over other warships is their affordability and speed. These boats, when armed with guided missiles, are c …
- 世界主要国のインフルエンザ検査（医療機器）市場：サプライヤーシェア及び市場予測The report presents a detailed analysis of the Influenza diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Influenza definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Com …
- Entyvio(潰瘍性大腸炎)：市場分析と予測（～2022）Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting …
- ダイ・レベル・パッケージング装置の世界市場2015-2019About Die-level Packaging ICs manufactured in the global semiconductor industry are delicate, and thus vulnerable to contamination causing malfunction. To prevent from such malfunctions, silicon chips or ICs are protected using packaging materials. Wafer-level packaging and die-level packaging are the most predominant packaging types. Wafer-level packaging involves the packaging of individual ICs …
- 世界の頭蓋顎顔面固定（CMF）装置市場動向（2012-2016）TechNavio's analysts forecast the Global CraniomaxilloFacial Fixation (CMF) Devices market to grow at a CAGR of 7.21 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing elderly population. The Global Cranio MaxilloFacial Fixation Devices market has also been witnessing the increasing demand for customized implants. However, the high cost o …
- 世界のワイヤレスオーディオデバイス市場2015The Global Wireless Audio Device Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Wireless Audio Device industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Wireless Audio Device market analysis is provided for the international markets including deve …
- 世界の鉛市場：市場規模、動向、メーカー動向Scope The report presents a thorough study of lead, covering both global and regional markets It aims to give a proper picture of the market, as well as its trends, perspectives and opportunities Comprehensive data showing lead production, consumption, trade statistics and prices are provided (both nationwide and worldwide) Each country’s market overview covers the following: lead production in th …
- 医療画像用ソフトウェアの世界市場2017-2021ABSTRACTAbout Medical Imaging Software Medical imaging is the process of creating visual representations of the interior of the human body for medical applications and clinical analysis. The medical imaging software enables the use of medical imaging devices for viewing and analyzing medical images. The increased adoption of medical imaging software in the diagnosis of chronic diseases is expected …
- 骨接合用機器の世界市場2016-2020About Osteosynthesis Devices Osteoporosis is one of the common metabolic bone diseases that make the bone porous and decreases bone strength, thus, making it fragile and weak. The older population is more vulnerable to osteoporosis as their body becomes less efficient at absorbing calcium and other nutrients. This can lead to susceptibility to spinal injuries, and distal radius and proximal femur …
- 世界のSCADA産業制御システム市場動向（2014-2018）About SCADA Supervisory control and data acquisition (SCADA) systems are used to monitor and control industrial processes and infrastructure in manufacturing plants. SCADA helps to gather information about different equipment’s across various industrial processes such as manufacturing, transportation, power generation, refining, and desalination in both discrete and process manufacturing industrie …
